247 related articles for article (PubMed ID: 26643872)
1. Genomic landscape of liposarcoma.
Kanojia D; Nagata Y; Garg M; Lee DH; Sato A; Yoshida K; Sato Y; Sanada M; Mayakonda A; Bartenhagen C; Klein HU; Doan NB; Said JW; Mohith S; Gunasekar S; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Myklebost O; Yang H; Dugas M; Meza-Zepeda LA; Silberman AW; Forscher C; Tyner JW; Ogawa S; Koeffler HP
Oncotarget; 2015 Dec; 6(40):42429-44. PubMed ID: 26643872
[TBL] [Abstract][Full Text] [Related]
2. Frequent amplification of receptor tyrosine kinase genes in welldifferentiated/ dedifferentiated liposarcoma.
Asano N; Yoshida A; Mitani S; Kobayashi E; Shiotani B; Komiyama M; Fujimoto H; Chuman H; Morioka H; Matsumoto M; Nakamura M; Kubo T; Kato M; Kohno T; Kawai A; Kondo T; Ichikawa H
Oncotarget; 2017 Feb; 8(8):12941-12952. PubMed ID: 28099935
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the 12q amplicons in lipomatous soft tissue tumors by multiplex ligation-dependent probe amplification-based copy number analysis.
Creytens D; Van Gorp J; Speel EJ; Ferdinande L
Anticancer Res; 2015 Apr; 35(4):1835-42. PubMed ID: 25862836
[TBL] [Abstract][Full Text] [Related]
4. High-resolution genomic mapping reveals consistent amplification of the fibroblast growth factor receptor substrate 2 gene in well-differentiated and dedifferentiated liposarcoma.
Wang X; Asmann YW; Erickson-Johnson MR; Oliveira JL; Zhang H; Moura RD; Lazar AJ; Lev D; Bill K; Lloyd RV; Yaszemski MJ; Maran A; Oliveira AM
Genes Chromosomes Cancer; 2011 Nov; 50(11):849-58. PubMed ID: 21793095
[TBL] [Abstract][Full Text] [Related]
5. Targeted next-generation sequencing of CIC-DUX4 soft tissue sarcomas demonstrates low mutational burden and recurrent chromosome 1p loss.
Lazo de la Vega L; Hovelson DH; Cani AK; Liu CJ; McHugh JB; Lucas DR; Thomas DG; Patel RM; Tomlins SA
Hum Pathol; 2016 Dec; 58():161-170. PubMed ID: 27664537
[TBL] [Abstract][Full Text] [Related]
6. Integrated genomic and transcriptomic analysis revealed mutation patterns of de-differentiated liposarcoma and leiomyosarcoma.
Liu W; Tong H; Zhang C; Zhuang R; Guo H; Lv C; Yang H; Lin Q; Guo X; Wang Z; Wang Y; Shen F; Wang S; Dai C; Wang G; Liu J; Lu W; Zhang Y; Zhou Y
BMC Cancer; 2020 Oct; 20(1):1035. PubMed ID: 33115433
[TBL] [Abstract][Full Text] [Related]
7. Oncogene mutation profiling reveals poor prognosis associated with FGFR1/3 mutation in liposarcoma.
Li C; Shen Y; Ren Y; Liu W; Li M; Liang W; Liu C; Li F
Hum Pathol; 2016 Sep; 55():143-50. PubMed ID: 27237367
[TBL] [Abstract][Full Text] [Related]
8. Concurrent exome-targeted next-generation sequencing and single nucleotide polymorphism array to identify the causative genetic aberrations of isolated Mayer-Rokitansky-Küster-Hauser syndrome.
Chen MJ; Wei SY; Yang WS; Wu TT; Li HY; Ho HN; Yang YS; Chen PL
Hum Reprod; 2015 Jul; 30(7):1732-42. PubMed ID: 25924657
[TBL] [Abstract][Full Text] [Related]
9. Estimation of copy number aberrations: Comparison of exome sequencing data with SNP microarrays identifies homozygous deletions of 19q13.2 and CIC in neuroblastoma.
Fransson S; Östensson M; Djos A; Javanmardi N; Kogner P; Martinsson T
Int J Oncol; 2016 Mar; 48(3):1103-16. PubMed ID: 26794043
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive mapping of p53 pathway alterations reveals an apparent role for both SNP309 and MDM2 amplification in sarcomagenesis.
Ito M; Barys L; O'Reilly T; Young S; Gorbatcheva B; Monahan J; Zumstein-Mecker S; Choong PF; Dickinson I; Crowe P; Hemmings C; Desai J; Thomas DM; Lisztwan J
Clin Cancer Res; 2011 Feb; 17(3):416-26. PubMed ID: 21159888
[TBL] [Abstract][Full Text] [Related]
11. Microarray-based copy number and expression profiling in dedifferentiated and pleomorphic liposarcoma.
Fritz B; Schubert F; Wrobel G; Schwaenen C; Wessendorf S; Nessling M; Korz C; Rieker RJ; Montgomery K; Kucherlapati R; Mechtersheimer G; Eils R; Joos S; Lichter P
Cancer Res; 2002 Jun; 62(11):2993-8. PubMed ID: 12036902
[TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of potential therapeutic targets in dedifferentiated liposarcoma.
Hanes R; Grad I; Lorenz S; Stratford EW; Munthe E; Reddy CC; Meza-Zepeda LA; Myklebost O
Oncotarget; 2016 Aug; 7(34):54583-54595. PubMed ID: 27409346
[TBL] [Abstract][Full Text] [Related]
13. Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis.
Cha S; Lee J; Shin JY; Kim JY; Sim SH; Keam B; Kim TM; Kim DW; Heo DS; Lee SH; Kim JI
BMC Cancer; 2016 Feb; 16():170. PubMed ID: 26925973
[TBL] [Abstract][Full Text] [Related]
14. Characterization of pancreatic ductal adenocarcinoma using whole transcriptome sequencing and copy number analysis by single-nucleotide polymorphism array.
Di Marco M; Astolfi A; Grassi E; Vecchiarelli S; Macchini M; Indio V; Casadei R; Ricci C; D'Ambra M; Taffurelli G; Serra C; Ercolani G; Santini D; D'Errico A; Pinna AD; Minni F; Durante S; Martella LR; Biasco G
Mol Med Rep; 2015 Nov; 12(5):7479-84. PubMed ID: 26397140
[TBL] [Abstract][Full Text] [Related]
15. Recurrent Genomic Alterations in Soft Tissue Perineuriomas.
Carter JM; Wu Y; Blessing MM; Folpe AL; Thorland EC; Spinner RJ; Jentoft ME; Wang C; Baheti S; Niu Z; Mauermann ML; Klein CJ
Am J Surg Pathol; 2018 Dec; 42(12):1708-1714. PubMed ID: 30303818
[TBL] [Abstract][Full Text] [Related]
16. Genomic alterations in BCL2L1 and DLC1 contribute to drug sensitivity in gastric cancer.
Park H; Cho SY; Kim H; Na D; Han JY; Chae J; Park C; Park OK; Min S; Kang J; Choi B; Min J; Kwon JY; Suh YS; Kong SH; Lee HJ; Liu ET; Kim JI; Kim S; Yang HK; Lee C
Proc Natl Acad Sci U S A; 2015 Oct; 112(40):12492-7. PubMed ID: 26401016
[TBL] [Abstract][Full Text] [Related]
17. HDACi inhibits liposarcoma via targeting of the MDM2-p53 signaling axis and PTEN, irrespective of p53 mutational status.
Ou WB; Zhu J; Eilers G; Li X; Kuang Y; Liu L; Mariño-Enríquez A; Yan Z; Li H; Meng F; Zhou H; Sheng Q; Fletcher JA
Oncotarget; 2015 Apr; 6(12):10510-20. PubMed ID: 25888633
[TBL] [Abstract][Full Text] [Related]
18. High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray.
Yin D; Ogawa S; Kawamata N; Tunici P; Finocchiaro G; Eoli M; Ruckert C; Huynh T; Liu G; Kato M; Sanada M; Jauch A; Dugas M; Black KL; Koeffler HP
Mol Cancer Res; 2009 May; 7(5):665-77. PubMed ID: 19435819
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma.
Singer S; Socci ND; Ambrosini G; Sambol E; Decarolis P; Wu Y; O'Connor R; Maki R; Viale A; Sander C; Schwartz GK; Antonescu CR
Cancer Res; 2007 Jul; 67(14):6626-36. PubMed ID: 17638873
[TBL] [Abstract][Full Text] [Related]
20. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas.
Rieske P; Bartkowiak JK; Szadowska AM; Olborski B; Harezga-Bal B; Debiec-Rychter M
J Exp Clin Cancer Res; 1999 Sep; 18(3):403-16. PubMed ID: 10606188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
